文献速递眼底病与葡萄膜炎

局部用阿克里扎尼(LHA510)——一种酪氨酸激酶VEGF受体抑制剂——在经治新生血管性年龄相关性黄斑变性受试者中的随机、双盲、多中心试验

A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2022-03-02

这项2期多中心随机双盲载体对照概念验证研究纳入90例正在接受抗VEGF治疗的活动性新生血管性年龄相关性黄斑变性患者,基线均接受雷珠单抗玻璃体腔注射,按1:1随机接受局部LHA510或载体12周(前8周每日2次,后4周每日3次)。扩展符合方案集70例中,LHA510组33例中25例(75.8%)与安慰剂组37例中25例(67.6%)在第84天前需要挽救治疗(P=0.8466),次要和亚组分析不支持疗效证据。

要点

  • LHA510组75.8%与安慰剂组67.6%在第84天前需要挽救治疗,差异无统计学意义(P=0.8466)。
  • 次要结局和亚组分析均不支持LHA510的疗效证据。
  • 46例接受LHA510治疗的患者中21例出现可逆性角膜混浊,停药后消退,以每日1次频率重新开始治疗的患者未复发。

核心结论

  • 尽管针对局部疗效进行了广泛优化,LHA510未能显示临床疗效。

研究设计与样本

  • 2期多中心随机双盲载体对照概念验证研究,纳入90例因新生血管性年龄相关性黄斑变性存在活动性脉络膜新生血管且正在接受抗VEGF治疗的患者。
  • 所有患者基线接受雷珠单抗玻璃体腔注射,出现疾病复发证据时进行挽救治疗;患者按1:1随机接受局部LHA510或载体12周,前8周每日2次,后4周每日3次。

主要发现

  • 扩展符合方案集70例中,LHA510组33例中25例(75.8%)与安慰剂组37例中25例(67.6%)在第84天前需要挽救治疗(P=0.8466)。
  • 次要和亚组分析不支持疗效证据。
  • 46例接受LHA510治疗的患者中21例出现可逆性角膜混浊,停药后消退,以每日1次频率重新开始治疗的患者未复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti-vascular endothelial growth factor therapy over a 12-week period in patients with neovascular age-related macular degeneration. DESIGN: A phase 2 multicenter randomized double-masked, vehicle-controlled proof-of-concept study. METHODS: Trial includes n = 90 patients with active choroidal neovascularization due to neovascular age-related macular degeneration and under anti-vascular endothelial growth factor treatment. All patients received an intravitreal injection of ranibizumab at baseline and were retreated when there was evidence of disease recurrence (rescue). Patients were randomized 1:1 to receive topical LHA510 or vehicle for 12 weeks. Drops were administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks. MAIN OUTCOME MEASURE: The primary outcome was the number of patients requiring rescue over 84 days of topical dosing. Key secondary outcome measures were time to first rescue, total number of ranibizumab injections, changes in central subfield thickness, and changes of visual acuity from baseline to day 84. RESULTS: The extended per protocol set included 70 patients of whom 25 of 33 patients in the LHA510 group (75.8%) and 25 of 37 patients in the placebo group (67.6%) required rescue by day 84 (P = .8466). Secondary and subgroup analysis did not support evidence of efficacy. Twenty-one of 46 patients administered LHA510 developed a reversible corneal haze that resolved with cessation of treatment and did not recur in patients restarted at once daily frequency. CONCLUSION: In spite of extensive optimization for topical efficacy, LHA510 failed to demonstrate clinical efficacy.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Poor SH, Weissgerber G, Adams CM, et al. A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022. PMID: 35247334. doi:10.1016/j.ajo.2022.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。